Premium
Activity of antimicrobial peptide mimetics in the oral cavity: I. Activity against biofilms of Candida albicans
Author(s) -
Hua J.,
Yamarthy R.,
Felsenstein S.,
Scott R.W.,
Markowitz K.,
Diamond G.
Publication year - 2010
Publication title -
molecular oral microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.18
H-Index - 77
eISSN - 2041-1014
pISSN - 2041-1006
DOI - 10.1111/j.2041-1014.2010.00590.x
Subject(s) - candida albicans , antimicrobial , fluconazole , biofilm , microbiology and biotechnology , fungicide , chemistry , biological activity , peptide , corpus albicans , antimicrobial peptides , antifungal , in vitro , biology , biochemistry , bacteria , genetics , botany
Summary Naturally occurring antimicrobial peptides hold promise as therapeutic agents against oral pathogens such as Candida albicans but numerous difficulties have slowed their development. Synthetic, non‐peptidic analogs that mimic the properties of these peptides have many advantages and exhibit potent, selective antimicrobial activity. Several series of mimetics (with molecular weight < 1000) were developed and screened against oral Candida strains as a proof‐of‐principle for their antifungal properties. One phenylalkyne and several arylamide compounds with reduced mammalian cytotoxicities were found to be active against C. albicans . These compounds demonstrated rapid fungicidal activity in liquid culture even in the presence of saliva, and demonstrated synergy with standard antifungal agents. When assayed against biofilms grown on denture acrylic, the compounds exhibited potent fungicidal activity as measured by metabolic and fluorescent viability assays. Repeated passages in sub‐minimum inhibitory concentration levels did not lead to resistant Candida , in contrast to fluconazole. Our results demonstrate the proof‐of principle for the use of these compounds as anti‐ Candida agents, and their further testing is warranted as novel anti‐ Candida therapies.